Naloxegol Health Outcome Post Authorisation Safety Study

TERMINATED

Status

10000

Enrollment

INDUSTRY

Sponsor class

Stopped Not feasible to reach the required number of patient cases by the defined end of data collection milestone (Q4 2022) knowing that the study completion was planned by the end of 2023

Conditions

Opioid Induced Constipation

Interventions

DRUG: naloxegol
DRUG: non-PAMORA laxative

Sponsor

Kyowa Kirin Pharmaceutical Development Ltd